A 6-Week Study Of PF-05175157 In Type 2 Diabetes Mellitus
Status:
Terminated
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
This study is designed to assess the safety, tolerability and pharmacodynamics of 6 weeks of
oral doses of PF-05175157 provided as monotherapy in subjects with type 2 diabetes mellitus.